ArticleInternational journal of general medicine2025
Predicting Glioma Recurrence Using 18F-FDG PET/CT, MRI, and Tumor Markers: A Combined Approach.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the combined predictive value of 18F-FDG PET/CT, MRI, and tumor markers for glioma recurrence. Methods: A retrospective analysis was conducted on the clinical data of 82 glioma patients treated at our hospital from January 2023 to April 2024. Patients were divided into Group A (n = 19, recurrence) and Group B (n = 63, no recurrence) based on whether recurrence occurred. All patients underwent 18F-FDG PET/CT to obtain maximum standardized uptake value (SUVmax) and lesion-to-normal tissue ratio (L/N). MRI was performed to measure the apparent diffusion coefficient (ADC) of the tumor parenchyma and cerebral blood flow (CBF). Serum samples were collected from all patients, and tumor markers, including monocyte-to-lymphocyte ratio (MLR) and neutrophil-to-lymphocyte ratio (NLR), were measured using an automated blood analyzer. Differences in SUVmax, L/N, ADC, CBF, MLR, and NLR levels between Groups A and B were compared. Spearman correlation analysis was used to assess the relationships between SUVmax, L/N, ADC, CBF, MLR, NLR, and glioma recurrence. Receiver operating characteristic (ROC) curves were plotted to evaluate the diagnostic value of each parameter for glioma recurrence. Results: Recurrent patients demonstrated significantly higher SUVmax, L/N, NLR, and MLR, alongside lower ADC and CBF (all P < 0.05). These parameters correlated with recurrence (SUVmax, L/N, NLR, MLR positively; ADC and CBF negatively; all P < 0.05). ROC analysis highlighted the superiority of combined modalities, achieving an AUC of 0.856, with higher sensitivity and specificity than individual markers. Conclusion: SUVmax, L/N, ADC, CBF, MLR, and NLR are correlated with glioma recurrence. The combined use of SUVmax, L/N, ADC, CBF, MLR, and NLR provides higher diagnostic value for glioma recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.